Sort
39,280 grants matching “leukemia”
Physical Activity to Modify Sequelae and QOL in Childhood ALL: A Nursing Trial
$1,023,985Cheryl Lorane Cox · St. Jude Children'S Research Hospital · R01 · FY2009 · CA
Immunotherapy of low grade lymphoid malignancies
$1,023,663Adrian U Wiestner · National Heart, Lung, And Blood Institute · ZIA · FY2019 · HL
Development of Novel Approaches to Optimize CAR T-cell Therapies for B-cell Malignancies
$1,023,609Nirali Shah · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development
$1,023,231Rajesh Krishnan · Oncternal Therapeutics, Inc. · R44 · FY2022 · CA
Nuclear Structure and Gene Expression
$1,023,075Gary S. Stein · University Of Vermont & St Agric College · P01 · FY2013 · CA
Establishing and Interpreting Abnormal DNA Methylation in Cancer
$1,022,083Peter A Jones · Van Andel Research Institute · R35 · FY2025 · CA
Cancer and Leukemia Group B-Leukemia Correlative Science
$1,021,680Michael A Caligiuri · Ohio State University · U10 · FY2006 · CA
Lymphoma Disease Discovery and Definition
$1,021,536Elaine Jaffe · Division Of Clinical Sciences - Nci · ZIA · FY2019 · CA
Targeting High-Risk Lymphoid Neoplasms
$1,021,025David Marc Weinstock · Dana-Farber Cancer Inst · R35 · FY2021 · CA
MolecularCellular Regulation of Hematopoiesis
$1,020,550Jonathan R Keller · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Leadership, Planning and Evaluation
$1,019,114Caryn Lerman · University Of Southern California · P30 · FY2022 · CA
IGF::OT::IGF RD - A CLOUD COMPUTING PLATFORM FOR CYTOMETRY, SBIR TOPIC 59, PHASE
$1,018,697Nikesh Kotecha · Cytobank, Inc. · N44 · FY2013 · HL
RAG-mediated DNA Damage Responses in Immune Development and Function
$1,017,792Jeffrey J Bednarski · Washington University · R01 · FY2025 · AI
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.
$1,017,478Martin Devenport · Oncoimmune, Inc. · R44 · FY2017 · CA
Mechanisms of Mammalian Epigenome Reprogramming
$1,017,276Todd Scott Macfarlan · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2014 · HD
Stem Cell Biology, Cancer Stem Cell Biology, and Cancer Immunotherapy
$1,016,525Irving Lerner Weissman · Stanford University · R35 · FY2021 · CA
Reading mitochondrial apoptotic signaling to identify active cancer therapeutics
$1,016,184Anthony G Letai · Dana-Farber Cancer Inst · R35 · FY2023 · CA
Advanced Prodrug Treatment for CML
$1,016,040Milton H. Werner · Inhibikase Therapeutics · R44 · FY2018 · CA
Clinical Research Core
$1,015,416Michael Keating · University Of California, San Diego · P01 · FY2010 · CA
Mouse Models of Myeloid Leukemia
$1,015,189Kevin M Shannon · University Of California, San Francisco · U01 · FY2006 · CA
Bio-Therapies for the Treatment of Cancer and Infectious Disease
$1,015,090David Fitzgerald · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
$1,015,049Kimberly Stegmaier · Dana-Farber Cancer Inst · R35 · FY2019 · CA
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
$1,015,048A Thomas Look · Dana-Farber Cancer Inst · R35 · FY2019 · CA
Family Studies
$1,014,835Margaret Tucker · Division Of Cancer Epidemiology And Genetics · ZIA · FY2016 · CA
ABNORMAL SIGNAL TRANSDUCTION IN HEMATOPOIETIC DISEASE
$1,014,748Dana-Farber Cancer Institute · P01 · FY2000 · DK